Not Yet Recruiting
Liposomal Irinotecan Combined With Sintilimab and Anlotinib in the Treatment of Recurrent or Persistent Ovarian Clear Cell Carcinoma
NCT07239622
- Conditions
- Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +14 more
- Locations
-
Not specified